NEW YORK, New York — October 3, 2025 — Leads & Copy — Titan Pharmaceuticals, Inc. and Black Titan Corporation have successfully closed their merger with TalenTec Sdn. Bhd. The combined entity’s shares will trade on the Nasdaq as NASDAQ: BTTC.
Under the terms of the Merger and Contribution and Share Exchange Agreement, Titan is now a Black Titan subsidiary, effective October 1, 2025. Titan’s common stock trading ceased on October 1, 2025. Black Titan’s shares began trading on Nasdaq on October 2, 2025.
Black Titan CEO Chay W. J. noted the merger signifies a new phase of innovation and global growth.
ARC Group Ltd. was the financial advisor to Black Titan Corporation.
Chay W. J.
Chief Executive Officer
(786) 769-7512
Source: Black Titan Corporation
Source: Black Titan Corporation
